Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13611610 | 0.98 | KDM4E (0.46) | KDM4EPOLBL3MBTL1THRBATM | |
| SCHEMBL1203989 | 0.84 | POLB (0.46) | KDM4EPOLBL3MBTL1THRBATM | |
| SCHEMBL334858 | 0.83 | KDM4E (0.39) | KDM4EPOLBL3MBTL1THRBATM | |
| SCHEMBL3988453 | 0.83 | POLB (0.48) | KDM4EPOLBL3MBTL1THRBATM | |
| SCHEMBL1675898 | 0.83 | KDM4E (0.45) | KDM4EPOLBL3MBTL1THRBATM | |
| SCHEMBL17706076 | 0.81 | KDM4E (0.44) | KDM4EPOLBL3MBTL1THRBATM | |
| SCHEMBL1675833 | 0.81 | KDM4E (0.44) | KDM4EPOLBL3MBTL1THRBATM | |
| SCHEMBL1675827 | 0.81 | KDM4E (0.44) | KDM4EPOLBL3MBTL1THRBATM | |
| SCHEMBL1675625 | 0.81 | KDM4E (0.47) | KDM4EPOLBL3MBTL1THRBATM | |
| SCHEMBL335026 | 0.80 | MMP8 (0.38) | KDM4EPOLBL3MBTL1THRBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| WO-2009067547-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | KDM4E 2195/4885POLB 40/4885L3MBTL1 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.